Last reviewed · How we verify

NCT03423524: PHY1801

Clinical Study to Investigate Visual Performance of a Hydrophobic Monofocal IOL After Bilateral Implantation

Completed NA Last updated 15 February 2022
What this trial tests

NA trial testing Micropure 1.2.3. in Cataract in 20 participants. Completed in 27 July 2021.

Timeline
2 May 2018
Primary endpoint
27 July 2021
27 July 2021

Quick facts

Lead sponsorBeaver-Visitec International, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date2 May 2018
Primary completion27 July 2021
Estimated completion27 July 2021
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Beaver-Visitec International, Inc.

Who can join

45 and older, any sex, with Cataract or Lens Opacities. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, non-randomised, open, controlled, single-center post-market clinical follow study about Micropure 1.2.3 IOL.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Micropure 1.2.3.

Trials testing the same drug.

Other recruiting trials for Cataract

Currently open trials in the same condition.

Other Beaver-Visitec International, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03423524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing